1,3-二甲基-4-氯-1H-吡唑[3,4-B]并吡啶-5-甲酸乙酯 | 20481-15-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 1,3-二甲基-4-氯-1H-吡唑[3,4-B]并吡啶-5-甲酸乙酯
• 中文别名: 1,3-二甲基-4-氯-1H-吡唑并[3,4-b]吡啶-5-甲酸乙酯
• 英文名称: ethyl 4-chloro-1,3-dimethylpyrazolo[3,4-b]pyridine-5-carboxylate
• 英文别名: ethyl 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate；Ethyl 4-chloro-1,3-dimethylpyrazolo<3,4-b>pyridine-5-carboxylate；ethyl 4-chloro-5,7-dimethylpyrazolo[3,4-b]pyridine-3-carboxylate；5-carbethoxy-4-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine；Ethyl 4-chloro-1,3-dimethyl-1H-pyrazolo [3,4-b]pyridine-5-carboxylate
• CAS: 20481-15-6
• 化学式: C₁₁H₁₂ClN₃O₂
• mdl: MFCD00067954
• 分子量: 253.688
• InChiKey: QJXXEUYFFZWYCX-UHFFFAOYSA-N

物化性质

• 熔点：
  89-90°C
• 沸点：
  356.0±37.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  57
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090

SDS

Name:	Ethyl 4-chloro-1 3-dimethyl-1H-pyrazolo[3 4-b]pyridine-5-carboxylate Material Safety Data Sheet
Synonym:
CAS:	20481-15-6

Section 1 - Chemical Product MSDS Name:Ethyl 4-chloro-1 3-dimethyl-1H-pyrazolo[3 4-b]pyridine-5-carboxylate Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
20481-15-6	Ethyl 4-chloro-1,3-dimethyl-1H-pyrazol	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 20481-15-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: light brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 89 - 90 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H12ClN3O2
Molecular Weight: 254

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 20481-15-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 20481-15-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 20481-15-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 20481-15-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3-二甲基-4-氯-1H-吡唑[3,4-B]并吡啶-5-甲酸乙酯 在 4-氟苯乙烯 、 C₁₈H₂₁OZn^(1-)*Cl^(1-)*Mg⁽²⁺⁾ 、 cobalt acetylacetonate 、 碘 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以65%的产率得到ethyl 4-iodo-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
  参考文献：
  名称：

  铁或共催化的Cl / Zn交换制备多官能锌有机金属化合物

  摘要：

  新的铁或钴催化的Cl / Zn交换反应可将芳基，杂芳基以及烷基氯直接转化为相应的锌试剂。该方法耐受诸如腈或酯的官能团。明显地，仲和叔烷基氯是用于Cl / Zn交换的合适的底物。

  DOI：

  10.1021/ol201100p
• 作为产物：
  描述：

  5-氨基-1,3-二甲基吡唑 在 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 7.0h， 生成 1,3-二甲基-4-氯-1H-吡唑[3,4-B]并吡啶-5-甲酸乙酯
  参考文献：
  名称：

  新型1H-吡唑并[3,4-b]吡啶氨基磷酸酯衍生物的合成与表征

  摘要：

  十二个新的 1 H-吡唑并 [3,4-b] 吡啶氨基磷酸酯衍生物在温和条件下通过氨基烷基氨基磷酸酯在 4-Cl 取代的吡唑并 [3,4-b] 吡啶上的亲核芳香取代反应以良好的产率合成。新化合物通过红外、 1 H、 13 C 和 31 P NMR 光谱和 HRMS 进行了表征。一种化合物的晶体结构通过 X 射线衍射解析，并显示出涉及氨基磷酸酯基团的分子间相互作用网络。

  DOI：

  10.3998/ark.5550190.p008.413

文献信息

• Pyrazolo[3,4-<i>b</i>]pyridines: Syntheses, reactions, and nuclear magnetic resonance spectra
  作者：Brian Maurice Lynch、Misbahul Ain Khan、Huk Chia Teo、Francisco Pedrotti

  DOI：10.1139/v88-074

  日期：1988.3.1

  2-Chloro-3-formylpyridine (2-chloronicotinaldehyde) was obtained by reduction of 2-chloro-3-cyanopyridine by Raney nickel and formic acid (3 1); this intermediate is inaccessible by the above N-oxidation route (peroxyacid oxidation of 3-formylpyridine yields pyridine-N-oxide 3-carboxylic acid). In the synthesis of the parent 1 from 2-chloro-3-formylpyridine, the yield was prejudiced by the formation

  2-氯-3-甲酰基吡啶（2-氯烟醛）由雷尼镍和甲酸（3 1）还原2-氯-3-氰基吡啶得到；该中间体无法通过上述 N-氧化途径获得（3-甲酰基吡啶的过氧酸氧化产生吡啶-N-氧化物 3-羧酸）。在由 2-氯-3-甲酰基吡啶合成母体 1 时，收率受到吖嗪物质 11 的形成的影响。
• Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
  申请人：Wyeth Holdings Corporation

  公开号：EP1279674A3

  公开（公告）日：2003-10-01

  Compounds of the formula are provided wherein P and Q are provided that when P is Q is and vice versa; which are useful in disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  提供了公式为的化合物，其中P和Q是，要求当P是Q时，Q也是P；这些化合物在由TNF-α介导的疾病条件中非常有用，例如类风湿关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和软骨退行性损失。
• Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
  申请人：American Cyanamid Company

  公开号：US06228869B1

  公开（公告）日：2001-05-08

  This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula: B wherein B is P and Q are provided that when P is Q is and vice versa; or a pharmaceutically acceptable salt thereof.

  这项发明提供了一种低分子量、非肽类的基质金属蛋白酶和TNF-α转化酶（TACE，肿瘤坏死因子-α转化酶）的抑制剂，其化学式为：B其中B是P和Q，当P为时，Q为，反之亦然；或其药用盐。
• Discovery of New Orally Active Phosphodiesterase (PDE4) Inhibitors
  作者：Hiroshi Ochiai、Akiharu Ishida、Tazumi Ohtani、Kensuke Kusumi、Katuya Kishikawa、Susumu Yamamoto、Hiroshi Takeda、Takaaki Obata、Hisao Nakai、Masaaki Toda

  DOI：10.1248/cpb.52.1098

  日期：——

  A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure–activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.

  合成了一系列4-氨基吡唑并吡啶衍生物，并对其作为磷酸二酯酶（PDE4）抑制剂进行生物评估。对3这一我们内部库中发现的结构新颖的化学先导物的化学改造主要集中在1-和3-取代基上。本文详细介绍了新型口服活性化学先导物5的发现，以及结构-活性关系数据、药理评估和亚型选择性研究的结果。
• [EN] N-HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS N-HÉTÉROARYLÉS
  申请人：INTERVET INT BV

  公开号：WO2012041873A1

  公开（公告）日：2012-04-05

  This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to novel N-heteroaryl compounds and the preparation of said compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

  这项发明涉及某些N-杂环芳基化合物，通常用作药物，更具体地用作动物药物。该药物可以优选用于治疗蠕虫感染和寄生虫病的治疗，例如由蠕虫感染引起的寄生虫病。该发明还涉及利用这些化合物制备药物和治疗方案，包括将这些化合物用于需要治疗的动物的给药。此外，该发明还涉及新型N-杂环芳基化合物及其制备。此外，该发明还涉及包含这些化合物的药物组合物和试剂盒。